@article{TCR13579,
author = {Jeffrey Zweig and Heather Wakelee},
title = {METLung: a disappointing result in a challenging patient population},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 3},
year = {2017},
keywords = {},
abstract = {The landscape of second line therapy and beyond for advanced non-small-cell lung cancer (NSCLC) continues to evolve. In addition to single agent chemotherapy following a platinum doublet, the use of second line tyrosine kinase inhibitors (TKIs) in patients with targetable molecular mutations, as well as the approval of programmed cell death 1 (PD-1) and programmed death ligands 1 (PDL-1) immunotherapies has greatly expanded the available options, making the clinical choice of a subsequent therapy increasingly complicated.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/13579}
}